Keryx Biopharmaceuticals Receives FDA Orphan Approval For Treatment of Neuroblastoma

by Benzinga Staff

July 14, 2010 9:39 AM | 12 seconds read | Make a Comment

Keryx Biopharmaceuticals

KERX

receives FDA approval for treatment of Neuroblastoma. Not FDA Approved for Orphan Indication Keryx Biopharmaceuticals is up close to 10% this morning. See Some of the Top Moving Indexes

Here.

Market News and Data brought to you by Benzinga APIs

Posted In: News FDA Markets Movers

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Keryx Biopharmaceuticals Receives FDA Orphan Approval For Treatment of Neuroblastoma